Viroporiners potentiale som lægemiddeltargets med fokus på SARS-CoV-2

Translated title of the contribution: The antiviral targeting potential of viroporins

John D Sund, Signe Bollerup, Jekob B Glamann, Caroline An Vinten, Louise R Jensen, Trine L Toft-Bertelsen, Bo H Bentzen, Thomas N Kledal, Nina Weis, Mette Rosenkilde

Research output: Contribution to journalReviewResearchpeer-review

12 Downloads (Pure)

Abstract

Viroporins are ion channels found in many viruses, where they contribute to virus life cycle and thereby pathogenesis. Viroporin targeting is a known, yet largely unexplored, therapeutic strategy so far only used in Influenza A with the drugs amantadine and rimantadine. In this review, we seek to utilize the inhibition by amantadine of the viroporin Protein E in SARS-CoV-2 in an attempt to treat COVID-19 in its early stages. We are executing a double-blinded placebo-controlled trial based on promising in vivo and in vitro work as a stepping-stone for establishing a therapeutic antiviral regime: blocking of viroporins.

Translated title of the contributionThe antiviral targeting potential of viroporins
Original languageDanish
Article numberV02220103
JournalUgeskrift for Laeger
Volume184
Issue number24
Number of pages8
ISSN0041-5782
Publication statusPublished - 13 Jun 2022

Cite this